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Background: Type 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk partly related to an
increase in inflammatory parameters. The aim of this study was to determine the association of inflammatory
biomarkers with low-density lipoprotein (LDL) subfraction phenotype and glycemic control in subjects with T2D
and poor glycemic control.
Methods: A cross-sectional study was performed comparing 122 subjects with T2D (59 ± 11 years old, body mass
index 30.2 ± 5.6 kg/m2) with 54 control subjects. Patients with T2D were classified according to their LDL
subfraction phenotype and inflammatory biomarkers (C-reactive protein, Interleukin-6, Interleukin-8, Transforming
growth factor β1, Monocyte chemotactic protein 1, Leptin, Adiponectin) were evaluated according to the degree of
glycemic control, LDL phenotype and other clinical characteristics. Forty-two subjects with T2D were studied before
and after 3 months of improving glycemic control by different strategies.
Results: Patients with T2D had higher C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP1) levels
and lower adiponectin concentration, compared to controls. T2D subjects with body mass index ≥ 30 kg/m2 had
higher CRP levels (5.2 ± 4.8 mg/l vs 3.7 ± 4.3 mg/l; p < 0.05). The presence of LDL phenotype B was related to higher
levels of transforming growth factor-β1 (TGF-β1) (53.92 ± 52.82 ng/l vs 31.35 ± 33.74 ng/l; p < 0.05) and lower
levels of adiponectin (3663 ± 3044 ng/l vs 2723 ± 1776 ng/l; p < 0.05). The reduction of HbA1c from 9.5 ± 1.8% at
baseline to 7.4 ± 0.8% was associated with a significant reduction of TGF-β1 (41.86 ± 32.84 ng/l vs 26.64 ± 26.91 ng/l;
p = 0.02).
Conclusions: Subjects with T2D, especially those with LDL phenotype B and obesity, have higher levels of
inflammatory biomarkers. Improvement of glycemic control reduces TGF-β1 levels, which may contribute partly to
its renoprotective role.
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Type 2 diabetes mellitus is one of the most common dis-
eases in occidental society and it is associated with a
high cardiovascular risk, not only due to the classical
factors but also to a chronic low-grade inflammation [1].
In this sense, epidemiological studies have demonstrated
an increase in plasma levels of inflammatory markers
such as CRP, IL-6 and TNF-α in patients with metabolic
syndrome and also in those with clinically overt T2D
[2,3]. Other molecules such as the transforming growth
factor (or tumor growth factor) β1 [4], MCP1 [5,6] or
LP-PLA2 [7] also present increased concentrations in
T2D subjects.
A genetic predisposition associated to excessive caloric
intake and a lack of physical excercise can lead to obes-
ity and central adiposity. Then, this may result in adi-
pose tissue dysfunction, macrophage infiltration and a
greater release of cytokines such as IL-6 and TNF-α.
Chronically elevated levels of these biomarkers promote
insulinresistance in skeletal muscle and endothelial dys-
function, as well as liberation of CRP from the liver [8].
Moreover, hyperglycaemia also induces IL-6 production
from endothelium and macrophages, which might
worsen insulin liberation and signaling cascades. This
suggests that improving glycemic control might reduce
the inflammatory response supporting the link between
inflammation and glucose metabolic disturbance.
On the other hand, previous studies have demon-
strated a significant correlation between CRP levels
and features of the metabolic syndrome, including adi-
posity, hyperinsulinemia, insulin resistance, hypertriglyc-
eridemia and low HDLc [9-11]. Interestingly, lifestyle
and pharmacological interventions in T2D such as sta-
tins, angiotensin receptor blockers and glitazones have
demonstrated a beneficial effect on markers of inflam-
mation [12-15]. However, the correlation between in-
flammatory markers and glycemic control is significant
in some studies [16,17] but not in others [18], and avail-
able information about the effect of an improvement of
glycemic control on inflammatory markers is very scarce
[19,20]. Moreover, the impact of the presence of the
atherogenic LDL subfraction phenotype, very common
in T2D, on inflammatory markers has not been previ-
ously analyzed in these subjects.
Therefore, the aim of this study was to determine the
association of inflammatory biomarkers with glycemic
control and LDL subfraction phenotype.
Methods
Patients
This report includes a cross-sectional study with 122
consecutive poor controlled T2D patients who attended
an out-patient diabetic clinic between 2007 and 2008 to
optimize glycemic control. Patients were selected on thebasis of poor glycemic control (HbA1C > 8.5%). As a
control group, we selected 54 normoglycemic and nor-
molipemic healthy subjects, without chronic pharmaco-
logical medication. This cohort of patients had been
studied previously [21,22]. Anthropometrical and clinical
characteristics of patients and controls, which have been
reported elsewhere [22], are shown in Table 1. Briefly,
previous pharmacological hypoglycemic treatment con-
sisted of diet only (22%), oral agents (21.1%), insulin plus
oral agents (29.4%) and insulin alone (27.5%). Pharmaco-
logical hypolipidemic treatment included statins (25.4%),
fibrates (4.1%), statins plus fibrates (2.5%) and statins
plus ezetimibe (1.6%). Patients with acute or chronic in-
fections, active inflammatory disease or treatment with
anti-inflammatory drugs were excluded. Subjects with
CRP higher than 20 mg/L were also excluded from the
study. A longitudinal study was also performed in a sub-
group of 42 subjects with T2D and poor glycemic con-
trol, defined as HbA1c > 8.5%, who were recruited
consecutively from the diabetes clinic [21]. All patients
were evaluated before and after 3 months of glycemic
optimization in a clinical practice setting with different
strategies, which included lifestyle counseling and in-
tensification of pharmacological hypoglycemic therapy
with oral agents (metformin or metformin plus sulpho-
nylurea) in 6 patients, insulin therapy in 31 patients or
both (insulin plus metformin or insulin plus metformin
and sulphonylurea) in 5 patients [21]. Lipid-lowering
and antihypertensive therapy was unchanged.
The study was performed in accordance with the prin-
ciples of the Declaration of Helsinki and was approved
by the Hospital’s ethics committee. All patients and con-
trols signed informed consent.
Laboratory analysis
Blood specimens were obtained after overnight fasting.
HbA1c was measured by ion-exchange high-performance
liquid chromatography (HPLC; variant II, Bio-Rad) with a
reference range of 4.6-5.8%. LDL subfraction phenotype
was determined by measuring LDL size, determined by
non-denaturing polyacrylamide gradient (2–16%) gel elec-
trophoresis, as described [23]. LDL subfraction phenotype
B was defined by a predominant LDL diameter lower than
25.5 nm, while phenotype A subjects had a LDL diameter
higher than 25.5 nm. C-reactive protein was measured by
a highly-sensitive commercial method (hsCRP, Roche
Diagnostics) in Hitachi 917 autoanalyzer. Interleukin 6,
IL-8, MCP1, TGF-β1, leptin and adiponectin were mea-
sured by ELISA from Bender Medsystems (IL-6, IL-8,
MCP1 and TGF-β1), or R&D (leptin and adiponectin).
Statistical analysis
Statistical analysis was performed using SPSS version
15.0 (SPSS Inc.). Before statistical analysis, normal
Table 1 Anthropometric and clinical characteristics of






Age (years) 56 ± 14 59 ± 11
Diabetes duration (years) - 10.61 ± 10.26
Chronic complications: -
● Retinopathy (%) 29.7
● Nephropathy (%)a 32.4
● Coronary Heart Disease (%) 9.9
Antihypertensive medication (%) - 67.9
Cholesterol lowering medication (%) - 33.6
Weight (kg) 69.3 ± 11.4 82.1 ± 18.8*
Waist (cm) 92 ± 11 105 ± 14*
Body mass index (Kg/m2) 25.9 ± 3.5 30.2 ± 5.6*
Data are expressed mean ± SD.
aNephropathy defined as impaired renal function (eGFR < 60 ml/minut) or 2 or
more urinary determinations of microalbuminuria ≥ 20 mg/l or ≥ 30 mg/g
of creatinine.
*Statistically significant (p <0.05).
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tested using Kolmogorov-Smirnov and Levène tests, re-
spectively. Data that were not normally distributed were
logarithmically transformed before analysis. Groups were
compared using Student’s unpaired t test for parameters
with normal distribution or Mann–Whitney test for pa-
rameters with non-normal distribution. The effect of gly-
cemic optimization was analyzed using Student’s paired t
test for parameters with normal distribution or Wil-
coxon test for parameters with non-normal distribution.
Correlations between parameters were analyzed using
the Pearson R test for variables with normal distribution
and the Spearman test for variables with non-normal
distribution. Data are expressed as mean ± standard des-
viation. P < 0.05 was considered significant.Table 2 Inflammation parameters of control subjects and pat
subfraction phenotype, at baseline: T2D: type 2 diabetes
T2D (N = 122) T2D phenotyp
C-reactive protein (mg/l) 4.49 ± 4.67 a 4.31 ±
Interleukin-6 (ng/l) 1.84 ± 3.99 2.24 ±
Interleukin-8 (ng/l) 15.91 ± 12.85 17.46 ±
Transforming growth factor β1 (ng/l) 41.19 ± 30.08 31.35 ±
Monocyte chemotactic protein 1 (ng/l) 198.0 ± 132.9 a 190.6 ±
Leptin (ng/l) 8980 ± 8194 9066 ±
Adiponectin (ng/l) 3272.0 ± 2671 a 3663 ±
Data are expressed mean ± SD.
a, P <0.05 vs control group; b, P <0.05 vs phenotype A patients.Results
Table 2 shows inflammation parameters of patients with
T2D and controls. T2D subjects had higher CRP and
MCP1 levels, and lower adiponectin concentrations than
controls. One third (n = 44) of patients with T2D pre-
sented phenotype B, in contrast to the control group in
which all subjects (n = 54) had phenotype A. Compared
to T2D patients with LDL phenotype A, subjects with
LDL phenotype B had higher concentrations of TGF-β1
(53.92 ± 52.82 ng/l vs 31.35 ± 33.74 ng/l; p < 0.05) and
lower of adiponectin (3663 ± 3044 ng/l vs 2723 ±
1776 ng/l; p < 0.05) (Table 2, Figure 1A). T2D subjects
with BMI ≥ 30 kg/m2 had higher CRP levels (5.2 ±
4.8 mg/l vs 3.7 ± 4.3 mg/l; p = 0.029), while those previ-
ously treated with metformin had lower levels of IL-6
(1.51 ± 3.86 ng/l vs 2.23 ± 4.4 ng/l; p = 0.046). There were
no differences between patients treated with or without
insulin and between those with or without lipid-
lowering medication (data not shown). No correlation
was found between glycemic control and inflammatory
biomarkers.
Table 3 and Figure 1B show clinical characteristics
and inflammatory biomarkers of a subgroup of T2D pa-
tients before and after glycemic optimization. After a
follow-up of 3 months, HbA1c decreased from 9.5 ±
1.8% to 7.4 ± 0.8%, without changes in body weight.
Improvement of glycemic control was associated with a
significant reduction of TGF-β1 (41.86 ± 32.84 ng/l vs
26.64 ± 26.91 ng/l; p = 0.02). However, changes in TGF-
β1 levels did not correlate with those observed in
HbA1c.
Discussion
The present study confirms the low grade systemic in-
flammation status in T2D patients which is related to
features of the metabolic syndrome. However, the main
and novel findings are related to increased levels of
TGF-β1 concentration in patients with LDL phenotype
B, compared to those with phenotype A, and itsients with type 2 diabetes mellitus, according LDL
e A (N = 77) T2D phenotype B (N = 45) Control group (N = 54)
4.52 4.86 ± 5.10 2.38 ± 3.30
4.95 1.17 ± 0.83 1.25 ± 1.05
13.74 13.20 ± 10.87 12.58 ± 9.29
33.74 53.92 ± 52.82 b 39.55 ± 42.86
125.6 212.1 ± 146.21 154.3 ± 83.0
8786 8787 ± 7184 7819 ± 5866
3044 2723 ± 1776 b 5369 ± 3297
(A)
(B)
Figure 1 TGFβ1 levels. TGFβ1 levels in type 2 diabetic patients
according LDL Phenotype (A), and before and after glycemic control
optimization (B). T2D: type 2 diabetes.
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trol. These findings suggest that TGF-β1 may be a link
to glycemic control and atherogenic dyslipidemia with
the development of diabetic nephropathy.
Systemic inflammation status in T2D subjects
The analysis of inflammatory parameters showed that
plasma concentrations of CRP and MCP1 were higher
and that of adiponectin was lower in T2D patients than
in control subjects. This observation indicates a greater
global systemic inflammation status in diabetic patients,
which has been previously suggested that may reflect the
activity of the underlying atherosclerotic process [24],
and it is concordant with several cross-sectional studies
which have shown an increase of CRP levels in patients
with diabetes [25-27]. Although the results reported in
the literature on the association between IL-6 and T2D
are contradictory [26,28,29], the absence of statistical
differences in IL-6 and other inflammatory parameters
could be related to the fact that most patients were
treated with medications such as metformin, antihyper-
tensive agents and lipid-lowering drugs, which have
demonstrated a beneficial effect on inflammation
[12-14]. In addition, the available information about the
relationship between inflammatory biomarkers and the
characteristics of the diabetes is limited. Some studies
have demonstrated significant correlation between CRPlevels with features of the metabolic syndrome, including
adiposity, hyperinsulinemia, insulin resistance, hypertri-
glyceridemia and low HDLc [9,30]. The preponderance
of small LDL particles (LDL phenotype B) is a compo-
nent of atherogenic dyslipidemia. In accordance, we have
observed that obese T2D subjects have higher CRP con-
centrations and inflammatory status was more unfavor-
able in patients with LDL phenotype B, who had higher
concentration of TGF-β1 and lower of adiponectin than
patients with phenotype A. To our knowledge, no other
studies have examined this association, but there are
some publications agreeing that serum levels of TGF-β1
are higher in patients with metabolic syndrome than
those without it [31] and that oxidized low-density lipo-
protein, which is increased in subjects with LDL pheno-
type B, is associated with TGF-β1 in T2D subjects [32].
Finally, TGFβ family members have been involved in
vascular remodeling defects in experimental models
[33], which could contribute to explain the worse prog-
nostic of atherosclerotic cardiovascular disease in dia-
betic patients.
The effect of improving glycemic control on markers of
inflammation in T2D
It has been shown that in the individuals with impaired
glucose tolerance [34] the low-grade chronic inflamma-
tion is related to glucose metabolic disturbance and a
growing body of evidence supports the hypothesis that
chronic systemic inflammation contributes to decrease
insulin sensitivity [35]. Moreover, hyperglycemia is a sig-
nificant stressor that has also been shown to cause
chronic inflammation [36]. However, the relationship be-
tween inflammatory markers and glycemic control is still
not fully understood. In our study, no inflammation
marker correlated with HbA1c levels. These results are
consistent with the findings of previous cross-sectional
studies which have found an inconsistent association be-
tween inflammation and blood glucose levels [16-18],
possibly due to previous treatment with metformin, sta-
tins and antihypertensive agents, which may limit the
power to detect an association between HbA1c and in-
flammatory markers. In the longitudinal study, we dem-
onstrated for the first time that improvement of
glycemic control by different therapeutic strategies can
lower TGF-β1 concentrations. These results are consist-
ent with the findings in diabetic rats treated with insulin
and with the increased expression of TGF-β1 receptor in
the diabetic kidney and in mesangial cells cultured in
high glucose [37,38]. The lack of significant correlation
between the magnitude of the reductions in HbA1c and
TGF-β1 after glycemic optimization may reflect differ-
ences in the relative importance of the local versus sys-
temic blood glucose levels, and it does not preclude an
underlying relationship between these two parameters.
Table 3 Clinical characteristics and inflammation
parameters of patients with type 2 diabetes mellitus




Age (years) 61 ± 12 -
Diabetes duration (years) 37 ± 14 -
Chronic complications:
● Retinopathy (%) 59 -
● Nephropathy (%) 51.3 -
● Coronary Heart Disease (%) 17.9 -
Insulin use (%) 75 85.7
Cholesterol lowering medication (%) 59.5 59.5
Weight (kg) 80.35 ± 19.52 80.02 ± 19.71
Body mass index (Kg/m2) 29.0 ± 5.8 28.8 ± 6
HbA1c (%) 9.5 ± 1.8 7.4 ± 0.8*
C-reactive protein (mg/l) 3.20 ± 2.86 3.15 ± 3.26
Interleukin-6 (ng/l) 1.49 ± 1.12 1.29 ± 0.70
Interleukin-8 (ng/l) 12.84 ± 7.57 13.82 ± 10.35
Transforming growth factor β1 (ng/l) 41.86 ± 32.84 26.64 ± 26.91*
Monocyte chemotactic protein 1 (ng/l) 224.31 ± 76.03 227.48 ± 132.79
Leptin (ng/l) 7594 ± 8852 7817 ± 7295
Adiponectin (ng/l) 3673 ± 3455 4084 ± 3927
Data are expressed mean ± SD.
*p <0.05 vs baseline.
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markers in our study cannot be attributed to weight gain
or pharmacological therapy, and confirms the results in
the few studies which have evaluated the effect of im-
proving glycemic control on markers of inflammation in
type 1 diabetes (DCCT) and T2D [19,20]. In the DCCT
study, intensive glycemic control was not associated with
changes in levels of CRP and among intensively treated
subjects who gained the most weight, there was a signifi-
cant rise. In T2D, in a study of 18 patients who had been
hospitalized to initiate insulin therapy because of poor
diabetes control, CRP values, but not MCP1 and fibrino-
gen levels, were decreased 2 weeks after initiation of in-
sulin therapy. This effect could result from anti-
inflammatory effects of insulin [18], although these find-
ings were not confirmed in the study of Pradhan et al.
[19]. They found that, in patients with recent-onset
T2D, treatment during 14 weeks with insulin glargine or
metformin compared with placebo did not reduce CRP,
IL-6 and soluble tumor necrosis factor receptor 2, des-
pite improving glucose control. In the present study, the
duration of the study was sufficient on the basis of as-
sessment of glycemic control by HbA1c, and a marked
improvement of glycemic control was obtained, beingnearly normal in most of the patients without changes in
body weight. Furthermore, lipid-lowering and antihyper-
tensive therapy was unchanged and in most patients in-
sulin therapy was the strategy used to improve glycemic
control.
The possible role of TGF-β1 in diabetic nephropathy
The critical role of hyperglycemia in the genesis of dia-
betic nephropathy has been established by cell culture
studies, experimental animal models, and clinical trials.
Certain cytokines have been identified as likely media-
tors of the effects of high ambient glucose on the kidney.
TGF-β1, a known pro-fibrotic factor, activates the pro-
duction of extracellular matrix by mesangial cells and
interstitial fibroblasts in the kidneys, and thus contrib-
utes to the manifestation of diabetic kidney disease
through a number of key pathological events leading to
reduced glomerular filtration and impaired renal func-
tion [39,40]. In mesangial cells, it has been demonstrated
that the expression and activity of TGF-β1 are directly
influenced by glucose levels [38]. Moreover, atherogenic
dyslipidemia is associated with the onset and progression
of nephropathy in T2D subjects, by a mechanism not
fully understood [41,42]. Therefore, the finding of a
higher concentration of TGF-β1 in patients with athero-
genic dyslipidemia provides a potential explanation.
In conclusion, the present study confirms that
low-grade chronic inflammation in T2D is related to
LDL phenotype B and obesity. In addition, our data
demonstrates that improvement of glycemic control re-
duces TGF-β1 levels, through an unknown mechanism.
These findings might support the role of TGF-β1 as a
likely mediator of the effects of high ambient glucose on
the kidney and the beneficial effects of strict glucose
control on the development of diabetic nephropathy.
However, future studies in larger groups of patients
should be performed to confirm these findings.
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